SALEM, Mass. — Commonwealth Diagnostics International (CDI) aims to improve access to accurate, non-invasive breath testing for functional GI disorders. As part of our ongoing commitment to expanding in-network coverage and ensuring affordability for patients, we are excited to announce that CDI is now in-network with Medica, a nonprofit health plan covering 1.5 million lives across 12 states.
Expanding Patient Access Across Key Regions
Medica provides health coverage for individuals, families, employers, and Medicare and Medicaid beneficiaries, with a strong presence in Arizona, Iowa, Kansas, Minnesota, Nebraska, North Dakota, Oklahoma, South Dakota, and Wisconsin, among other states. With this new partnership, more patients in these states can now access CDI’s clinically validated, FDA-registered, ISO 13485-certified hydrogen and methane breath testing at a significantly reduced out-of-pocket cost.
Growing Our Network for Greater Affordability
CDI continues prioritizing in-network expansion to make our SIBO, IMO, and carbohydrate malabsorption breath tests more affordable and accessible. In 2024, we added Blue Cross and Blue Shield of Illinois, CareFirst BlueCross BlueShield, and Premera Blue Cross to our growing list of in-network commercial payors. Now, we are furthering this effort with Medica by providing increased access in the Midwest and additional regions where Medica operates.
Additionally, CDI remains in-network with Medicare, Medicare Advantage, and Tricare, ensuring fully covered testing with no balance billing for eligible patients.
A Commitment to Supporting Providers and Patients
CDI’s partnership with Medica is another step toward reducing financial barriers to critical functional GI diagnostic testing while providing healthcare providers with best-in-class support:
✅ One-business-day results turnaround – the fastest in the industry
✅ Seamless ordering and test management through MyGI Gateway
✅ Expanded patient resources, including multilingual instructional guides and enhanced customer support
As we continue expanding our national payer footprint, CDI remains dedicated to delivering accurate, reliable, cost-effective breath testing solutions to healthcare providers and their patients.
See Our Full List of In-Network Payors
Visit our Billing & Insurance page to explore our growing list of in-network insurance partners and learn more about coverage in your region.
For more information about CDI’s breath testing solutions, contact our Provider Services Team at providerservices@commdx.com or 888-258-5966.
About Commonwealth Diagnostics International, Inc. (CDI):
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose familiar sources of digestive distress and functional GI ailments for adults and pediatric patients. Focused on their patient-centric principles, their cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Their expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as technology solutions, including MyGI Gateway, a cutting-edge provider portal for enhanced patient care, and MyGI Health, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. CDI manufactures its clinically validated, FDA-registered and CE marked breath test kits according to ISO 13485 standards and perform all diagnostics in our state-of-the-art, CLIA-certified lab utilizing proprietary diagnostic technologies. For more information, visit commdx.com.
